Amneal Pharmaceuticals, Inc.
AMRX
$11.82
-$0.37-3.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.93B | 2.85B | 2.83B | 2.79B | 2.68B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.93B | 2.85B | 2.83B | 2.79B | 2.68B |
| Cost of Revenue | 1.84B | 1.79B | 1.80B | 1.78B | 1.70B |
| Gross Profit | 1.09B | 1.07B | 1.03B | 1.02B | 979.05M |
| SG&A Expenses | 509.06M | 489.93M | 482.13M | 476.44M | 456.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.24M | -6.15M | -6.15M | -930.00K | -930.00K |
| Total Operating Expenses | 2.55B | 2.47B | 2.47B | 2.44B | 2.34B |
| Operating Income | 385.18M | 380.75M | 365.13M | 349.29M | 340.70M |
| Income Before Tax | 68.66M | 89.30M | 58.00M | -55.01M | -123.16M |
| Income Tax Expenses | 11.04M | 38.06M | 25.58M | 18.86M | 23.32M |
| Earnings from Continuing Operations | 57.62 | 51.24 | 32.42 | -73.88 | -146.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -51.72M | -47.87M | -45.47M | -43.01M | -37.98M |
| Net Income | 5.90M | 3.38M | -13.05M | -116.89M | -184.45M |
| EBIT | 385.18M | 380.75M | 365.13M | 349.29M | 340.70M |
| EBITDA | 625.66M | 626.11M | 605.95M | 585.48M | 567.69M |
| EPS Basic | 0.02 | 0.01 | -0.04 | -0.38 | -0.68 |
| Normalized Basic EPS | 0.07 | 0.02 | -0.04 | -0.07 | 0.02 |
| EPS Diluted | 0.02 | 0.01 | -0.04 | -0.38 | -0.69 |
| Normalized Diluted EPS | 0.07 | 0.02 | -0.04 | -0.07 | 0.02 |
| Average Basic Shares Outstanding | 1.25B | 1.24B | 1.24B | 1.24B | 1.17B |
| Average Diluted Shares Outstanding | 1.28B | 1.27B | 1.26B | 1.25B | 1.18B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |